Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Merck and Pfizer combination therapy improves kidney cancer survival

Merck’s Keytruda in combination with Pfizer’s Inlyta boosts survival in kidney cancer patients. Credit: Yale Rosen.

  • Merck, Pfizer combination therapy improves survival in kidney cancer

Go Top